Novo Nordisk (NYSE:NVO): Q2 EBIT +45% to 7.65B Danish kroner ($1.27B) vs. consensus of 6.65B...

Novo Nordisk (NYSE:NVO): Q2 EBIT +45% to 7.65B Danish kroner ($1.27B) vs. consensus of 6.65B kroner. Net profit +30% to 5.35B kroner vs. 4.87B kroner. Sales +21.7% to 19.47B kroner vs. 18.89B kroner. Sales of diabetes drug Victoza +83%, modern insulins +23%, both beating forecasts. Raises FY sales growth to 9-12% from 8-11%, op profit growth to 15% from at least 10%. (PR)